<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996615</url>
  </required_header>
  <id_info>
    <org_study_id>AI-BMRI</org_study_id>
    <nct_id>NCT04996615</nct_id>
  </id_info>
  <brief_title>AI Analysis for MR in Screening Breast Cancer in High-risk Women</brief_title>
  <official_title>Peking University People's Hospital Breast Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use radiomic analysis and Convolutional Neural Networks Analysis for Classification of&#xD;
      Contrast-enhancing Lesions at Multiparametric Breast MRI. Build an abbreviated protocal, and&#xD;
      investigate whether an abbreviated protocol was suitable for breast magnetic resonance&#xD;
      imaging screening for breast cancer in high-risk Chinese women, which can shorten the&#xD;
      examination time and avoid enhanced imaging while ensuring the accuracy of the diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>screening yield</measure>
    <time_frame>5 years</time_frame>
    <description>compare the rates of detection of breast cancers in the screening of high-risk populations between the BMRI full sequence, contrast-enhanced and non-contrast-enhanced sequence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The accuracy of radiologists and deep learning models</measure>
    <time_frame>5 years</time_frame>
    <description>compare the sensitivity，specificity， positive predictive value and negative predictive value of breast tumor detection by radiologists and deep learning models.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>high risk population</arm_group_label>
    <description>women at high risk of breast cancer undergoing enhanced MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>high risk population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        23&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing full sequence BMRI examination&#xD;
&#xD;
          -  Written informed consent and complete the clinical data questionnaire&#xD;
&#xD;
          -  Through the follow-up database, at least 6 months of follow-up results can be obtained&#xD;
             to determine whether the diagnosis result is negative/benign/malignant; for patients&#xD;
             who need pathological biopsy, the pathological biopsy results shall prevail to&#xD;
             determine the lesion benign/malignant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The breast had received radiotherapy, chemotherapy, biology and other treatments&#xD;
             before BMRI.&#xD;
&#xD;
          -  Signs or symptoms of breast disease&#xD;
&#xD;
          -  There are contraindications for breast-enhanced MRI examinations such as allergy to&#xD;
             contrast agents.&#xD;
&#xD;
          -  Patients during lactation or pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shu wang, doctor</last_name>
    <phone>86+010-88324010</phone>
    <email>shuwang@pkuph.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking university people's hospital</name>
      <address>
        <city>Beijing</city>
        <state>Bei Jing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan peng</last_name>
      <phone>13671287670</phone>
      <email>13671287670@163.com</email>
    </contact>
    <investigator>
      <last_name>Shu Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuan peng, MD</last_name>
      <phone>86+010-88324010</phone>
      <email>13671287670@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Shu Wang</investigator_full_name>
    <investigator_title>Director of Breast Center</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>screening</keyword>
  <keyword>high risk women</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>deep learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

